Eledon's Tegoprubart Shows Superior Kidney Function Preservation in Phase 1b Transplant Trial
核心洞察
Eledon Pharmaceuticals reported updated Phase 1b trial data for tegoprubart, an anti-CD40L (搜索) antibody, showing superior kidney function preservation with mean eGFR of 70.5 mL/min/1.73m² compared to standard care's 50 mL/min/1.73m².
The immunosuppressive therapy demonstrated favorable safety profile with no cases of hyperglycemia (搜索), diabetes (搜索), or tremor commonly associated with calcineurin inhibitors (搜索), though three patients discontinued due to adverse events.
Two patients completing 12 months of treatment maintained excellent kidney function with eGFRs above 90 mL/min/1.73m², supporting tegoprubart's potential as next-generation immunosuppression for kidney transplant recipients.
Eledon Pharmaceuticals presented encouraging updated data from its ongoing Phase 1b trial evaluating tegoprubart for preventing kidney transplant rejection (搜索), demonstrating superior organ function preservation compared to standard immunosuppressive therapy. The results, presented at the American Transplant Congress in Philadelphia, show the anti-CD40L (搜索) antibody maintaining kidney function significantly above historical benchmarks while exhibiting a favorable safety profile.
Superior Kidney Function Preservation
Data from 13 participants in the Phase 1b trial revealed that tegoprubart achieved an overall mean estimated glomerular filtration rate (eGFR) of 70.5 mL/min/1.73m² across all reported time points after day 30 post-transplant. This represents a substantial improvement over historical data from standard calcineurin inhibitor-based immunosuppression therapy, which typically reports aggregate mean eGFRs of approximately 50 mL/min/1.73m² during the first year after kidney transplant.
The trial demonstrated consistent kidney function preservation, with mean eGFR measured above 60 mL/min/1.73m² at all reported time points after day 30 post-transplant. Notably, two participants who completed 12 months on therapy post-transplant both demonstrated mean eGFRs above 90 mL/min/1.73m² at one-year post-transplant, indicating excellent long-term organ function.
Favorable Safety Profile
Tegoprubart demonstrated a generally safe and well-tolerated profile in patients undergoing de novo kidney transplantation. The treatment showed notable advantages over current standard care, with no reported cases of hyperglycemia (搜索), new onset diabetes (搜索), or tremor—side effects commonly associated with standard immunosuppression therapy.
However, three subjects discontinued the study due to adverse events including hair loss and fatigue, viral infection, and rejection, respectively. Importantly, there have been no cases of graft loss or death reported in the trial.
Addressing Current Treatment Limitations
"Calcineurin inhibitors (搜索), the current standard of care, do not adequately serve the transplant community due to frequent and difficult-to-manage side effects," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "By contrast, tegoprubart's observed clinical profile to date gives us confidence in its potential to supplant calcineurin inhibitors as a next-generation immunosuppression agent for patients who have received a new kidney."
Mechanism and Development Pipeline
Tegoprubart is an anti-CD40L (搜索) antibody with high affinity for the CD40 Ligand, a well-validated biological target with broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.
Eledon is currently conducting multiple studies to evaluate tegoprubart, including the ongoing Phase 1b trial (NCT05027906), the Phase 2 BESTOW trial (NCT05983770), and a long-term safety and efficacy extension study (NCT06126380). The company anticipates completing enrollment in the Phase 2 BESTOW trial by the end of the year.
Clinical Development Progress
"Eledon continues to build a robust set of encouraging results demonstrating the safety and efficacy of tegoprubart in kidney transplant recipients in our Phase 1b trial," Gros noted. The company is building upon deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (搜索) (ALS).
The updated data from the April 2024 cutoff date continues to support tegoprubart's potential to protect organ function in patients undergoing kidney transplantation, positioning it as a promising alternative to current immunosuppressive regimens that carry significant side effect burdens.